Clinical Trials Sponsored by Immunex/Berlex

Total 3496 results

Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Cystic Fibrosis

United States, Spain, Australia, United Kingdom, Germany, Ireland
Vertex Pharmaceuticals Incorporated

Approved for marketing

Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
Berlin Heart, Inc

Unknown

Registry to Monitor Berlin Heart EXCOR® Pediatric VAD as a Bridge to Cardiac Transplantation.

Ventricular Dysfunction | Ventricular Dysfunction, Left | Ventricular Dysfunction, Right

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

Cystic Fibrosis

United States, Canada
Berlin Cures GmbH

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects

Healthy Volunteers

Germany
Herlev Hospital
GENIS

Terminated

Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (CHIPAC)

Pancreatic Cancer

Denmark
Vertex Pharmaceuticals Incorporated

Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Cystic Fibrosis

United States, United Kingdom, Germany, Spain, Switzerland, Canada, Netherlands, Italy, Ireland, Sweden, France, Denmark
Vertex Pharmaceuticals Incorporated

Completed

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Cystic Fibrosis | Advanced Lung Disease

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
University of Bergen

Completed

Giardia Induced Fatigue and Functional Gastrointestinal Diseases (GIFF)

Chronic Fatigue Syndrome

Norway
University of Bergen

Completed

Randomized Controlled Trial on the Treatment Effects of Melatonin and Light Therapy on Delayed Sleep Phase Syndrome

Delayed Sleep Phase Syndrome

Norway
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, Germany, Canada, Netherlands, Czech Republic, Italy, Ireland, Sweden, United Kingdom, Australia, France
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

Cystic Fibrosis

United States, Belgium, Canada, Netherlands, Germany
University of Bergen

Completed

Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine

Acute Myelogenous Leukemia

Norway
Vertex Pharmaceuticals Incorporated

Terminated

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype (CONCISE)

Hepatitis C, Chronic

United States, Austria, Canada, Germany, Israel, Poland
Helse-Bergen HF

Withdrawn

Ureteroscopy With and Without Safety Guidewire

Urolithiasis

Norway
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Chronic Hepatitis C

United States, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects

Healthy | Hepatic Impairment

Slovakia, Czech Republic
Freie Universität Berlin

Completed

Stage-based Exercise Promotion Study (STEPS)

Obesity | Diabetes Mellitus, Type 2

Germany
Vertex Pharmaceuticals Incorporated

Approved for marketing

VX-770 Expanded Access Program

Cystic Fibrosis
Biolex Therapeutics, Inc.

Completed

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV (SELECT-2)

Hepatitis C, Chronic

United States, Bulgaria, Puerto Rico, Romania
Biolex Therapeutics, Inc.

Completed

480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV) (480S)

Hepatitis C, Chronic

Bulgaria, Romania, Israel
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects

In Development for Cystic Fibrosis

Czech Republic, Slovakia
University of Bergen

Completed

Cost and Cost-effectiveness of PTB+ Treatment in Southern Ethiopia

Smear-positive TB Cases

Ethiopia
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

Cystic Fibrosis

United States
Berlin-Chemie Menarini

Completed

Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol (ENESYS)

Primary Arterial Hypertension

Romania
University of Bergen

Completed

Cognitive-Behavioural and Hypnotic Treatment of Chronic Primary Insomnia Among the Elderly

Insomnia

Norway
Mylan Bertek Pharmaceuticals

Completed

Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans

Hypertension

United States
Vertex Pharmaceuticals Incorporated

Completed

VX-950 and Peginterferon for Hepatitis C

Hepatitis C

Germany, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Hepatitis C

United States, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

Psoriasis
University of Bergen

Completed

Cognitive Behavioral Therapy for Anxiety and Depression in COPD

Depression | Chronic Obstructive Pulmonary Disease | Anxiety

Norway
Mylan Bertek Pharmaceuticals

Completed

Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

Parkinson Disease
Mylan Bertek Pharmaceuticals

Completed

A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.

Parkinson Disease
Mylan Bertek Pharmaceuticals

Completed

Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease

Parkinson Disease

United States
Charite University, Berlin, Germany
Berlin Institute of Health

Recruiting

TransCranial Doppler for REDUCtion of Silent strokE During MitraClip Implantation (TCD-REDUCE)

Mitral Valve Insufficiency

Germany
International Psychoanalytic University Berlin
Charite University, Berlin, Germany

Terminated

Biological Function of Dreaming in Dreaming and Non-Dreaming Patients With PCA Infarction (BFD)

Dream Disorder | Thrombotic Infarction | PCA Infarct

Germany
Charite University, Berlin, Germany
Berlin Institute of Health

Active, not recruiting

Urinary T Cell Biomarker for Prediction in ANCA Glomerulonephritis

Glomerulonephritis Acute

United Kingdom, Germany
Humboldt-Universität zu Berlin
Charite University, Berlin, Germany

Completed

Effectiveness of Isometric vs. Eccentric Exercise in Chronic Achilles Tendinopathy

Tendinopathy

Germany
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Leukemia | Non-Hodgkin Lymphoma of Intestine

China
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 (Trident19-H)

Non-hodgkin Lymphoma,B Cell

China
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Pain

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Sickle Cell Disease
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis

United Kingdom, Canada

3

Subscribe